The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma
Abstract To evaluate the clinical value of polyethylene glycolized recombinant human granulocyte-stimulating factor (PEG-rhG-CSF) for hematopoietic reconstitution after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) patients. This study analyzed data from 70 N...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-15360-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226256955998208 |
|---|---|
| author | Ruiqi Wang Hao Tian Zhenxing Zhu Dan Cong Yuansong Bai Wenlong Zhang |
| author_facet | Ruiqi Wang Hao Tian Zhenxing Zhu Dan Cong Yuansong Bai Wenlong Zhang |
| author_sort | Ruiqi Wang |
| collection | DOAJ |
| description | Abstract To evaluate the clinical value of polyethylene glycolized recombinant human granulocyte-stimulating factor (PEG-rhG-CSF) for hematopoietic reconstitution after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) patients. This study analyzed data from 70 NDMM patients undergoing ASCT, with 33 receiving PEG-rhG-CSF and 37 receiving rhG-CSF. The median time of neutrophil and platelet engraftment, median transfusions of blood products, treatment-related adverse reactions, long-term hematopoietic reconstitution and economic benefits were compared between the two groups. Both groups had similar median neutrophil engraftment, but PEG-rhG-CSF resulted in slower platelet engraftment (13.7 vs. 11.4 days, p < 0.001), more platelet transfusions (2.9 vs. 1.6 units, p < 0.001), higher incidence of grade ≥ 3 diarrhea (60.6 vs. 29.7%, p = 0.006), longer diarrhea duration (9.0 vs. 5.5 days, p = 0.004), and higher costs (RMB 77,126 vs. RMB 68,361, p = 0.027). PEG-rhG-CSF support post-ASCT in NDMM led to slower platelet engraftment, greater platelet transfusion requirements, increased incidence and duration of severe diarrhea, and greater costs, indicating its potential as an expensive treatment option. |
| format | Article |
| id | doaj-art-153dfb31795b4cfaa1f8b3e888ca70bf |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-153dfb31795b4cfaa1f8b3e888ca70bf2025-08-24T11:28:21ZengNature PortfolioScientific Reports2045-23222025-08-0115111010.1038/s41598-025-15360-7The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myelomaRuiqi Wang0Hao Tian1Zhenxing Zhu2Dan Cong3Yuansong Bai4Wenlong Zhang5Department of Hematology and Oncology, China-Japan Union Hospital of Jilin UniversityDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin UniversityDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin UniversityDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin UniversityDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin UniversityDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin UniversityAbstract To evaluate the clinical value of polyethylene glycolized recombinant human granulocyte-stimulating factor (PEG-rhG-CSF) for hematopoietic reconstitution after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) patients. This study analyzed data from 70 NDMM patients undergoing ASCT, with 33 receiving PEG-rhG-CSF and 37 receiving rhG-CSF. The median time of neutrophil and platelet engraftment, median transfusions of blood products, treatment-related adverse reactions, long-term hematopoietic reconstitution and economic benefits were compared between the two groups. Both groups had similar median neutrophil engraftment, but PEG-rhG-CSF resulted in slower platelet engraftment (13.7 vs. 11.4 days, p < 0.001), more platelet transfusions (2.9 vs. 1.6 units, p < 0.001), higher incidence of grade ≥ 3 diarrhea (60.6 vs. 29.7%, p = 0.006), longer diarrhea duration (9.0 vs. 5.5 days, p = 0.004), and higher costs (RMB 77,126 vs. RMB 68,361, p = 0.027). PEG-rhG-CSF support post-ASCT in NDMM led to slower platelet engraftment, greater platelet transfusion requirements, increased incidence and duration of severe diarrhea, and greater costs, indicating its potential as an expensive treatment option.https://doi.org/10.1038/s41598-025-15360-7Recombinant human granulocyte stimulating factorNewly diagnosed multiple myelomaAutologous stem cell transplantationHematopoietic reconstitution |
| spellingShingle | Ruiqi Wang Hao Tian Zhenxing Zhu Dan Cong Yuansong Bai Wenlong Zhang The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma Scientific Reports Recombinant human granulocyte stimulating factor Newly diagnosed multiple myeloma Autologous stem cell transplantation Hematopoietic reconstitution |
| title | The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma |
| title_full | The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma |
| title_fullStr | The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma |
| title_full_unstemmed | The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma |
| title_short | The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma |
| title_sort | hidden costs of peg rhg csf in autologous stem cell transplantation for newly diagnosed multiple myeloma |
| topic | Recombinant human granulocyte stimulating factor Newly diagnosed multiple myeloma Autologous stem cell transplantation Hematopoietic reconstitution |
| url | https://doi.org/10.1038/s41598-025-15360-7 |
| work_keys_str_mv | AT ruiqiwang thehiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT haotian thehiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT zhenxingzhu thehiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT dancong thehiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT yuansongbai thehiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT wenlongzhang thehiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT ruiqiwang hiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT haotian hiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT zhenxingzhu hiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT dancong hiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT yuansongbai hiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma AT wenlongzhang hiddencostsofpegrhgcsfinautologousstemcelltransplantationfornewlydiagnosedmultiplemyeloma |